About:Aripiprazole/sertraline

An Entity of Type:combination drug,from Named Graph:http://dbpedia.org,within Data Space:dbpedia.org

Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of aripiprazole (Abilify), an atypical antipsychotic, and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), which was under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD). It combines serotonin reuptake inhibition from sertraline and modulation of dopamine and serotonin receptors from aripiprazole. In July 2017, it was in preregistration in Japan for the treatment of MDD. However, in September 2018, the regulatory submission in Japan for MDD was withdrawn.

Property	Value
dbo:abstract	Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of aripiprazole (Abilify), an atypical antipsychotic, and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), which was under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD). It combines serotonin reuptake inhibition from sertraline and modulation of dopamine and serotonin receptors from aripiprazole. In July 2017, it was in preregistration in Japan for the treatment of MDD. However, in September 2018, the regulatory submission in Japan for MDD was withdrawn. (en)
dbo:wikiPageID	53980585 (xsd:integer)
dbo:wikiPageLength	3049 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1113744109 (xsd:integer)
dbo:wikiPageWikiLink	dbc:Atypical_antipsychotics dbr:Dopamine_receptor dbr:List_of_investigational_antidepressants dbc:Abandoned_drugs dbr:Oral_administration dbr:Major_depressive_disorder dbr:5-HT_receptor dbc:Antidepressants dbr:Otsuka_Pharmaceutical dbr:Japan dbr:Aripiprazole dbr:Atypical_antipsychotic dbc:Combination_drugs dbr:Olanzapine/fluoxetine dbr:Selective_serotonin_reuptake_inhibitor dbr:Sertraline dbr:Serotonin_reuptake_inhibitor dbr:Combination_formulation
dbp:class	dbr:Atypical_antipsychotic dbr:Selective_serotonin_reuptake_inhibitor
dbp:component	Aripiprazole (en) Sertraline (en)
dbp:legalUs	IND (en)
dbp:routesOfAdministration	dbr:Oral_administration
dbp:synonyms	ASC-01 (en)
dbp:type	combo (en)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Nervous-system-drug-stub dbt:Reflist dbt:Serotonin_receptor_modulators dbt:Short_description dbt:Antidepressants dbt:Dopamine_receptor_modulators dbt:Monoamine_reuptake_and_release_modulators
dcterms:subject	dbc:Atypical_antipsychotics dbc:Abandoned_drugs dbc:Antidepressants dbc:Combination_drugs
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:CombinationDrug dbo:Drug
rdfs:comment	Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of aripiprazole (Abilify), an atypical antipsychotic, and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), which was under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD). It combines serotonin reuptake inhibition from sertraline and modulation of dopamine and serotonin receptors from aripiprazole. In July 2017, it was in preregistration in Japan for the treatment of MDD. However, in September 2018, the regulatory submission in Japan for MDD was withdrawn. (en)
rdfs:label	Aripiprazole/sertraline (en)
owl:sameAs	yago-res:Aripiprazole/sertraline wikidata:Aripiprazole/sertraline https://global.dbpedia.org/id/2oX1t
prov:wasDerivedFrom	wikipedia-en:Aripiprazole/sertraline?oldid=1113744109&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Aripiprazole/sertraline
isdbo:wikiPageRedirects of	dbr:Sertraline/aripiprazole dbr:ASC-01
isdbo:wikiPageWikiLink of	dbr:Olanzapine/fluoxetine dbr:Sertraline/aripiprazole dbr:ASC-01
isfoaf:primaryTopic of	wikipedia-en:Aripiprazole/sertraline

Movatterモバイル変換

About:Aripiprazole/sertraline